pMDI Pressurised Metered Dose Inhalers

Meet your innovation partner with a legacy of excellence

Bespak is a market leader in pMDIs. Backed by 60 years of experience in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), metering valves and actuators, we’re at the forefront of the transition to next-generation sustainable inhalers.

Leading the green transition

We’re committed to leading the change to climate-friendly propellants, so we can all breathe a little easier.  In fact, we’re so committed, we’ve not only developed our market-leading valves and actuators to optimise the delivery of low GWP formulations, we’ve invested heavily in our manufacturing assets to ensure we’re among the first sites in the world to manufacture with both sustainable propellant candidates HFA-152a and HFO-1234ze. We actively collaborate across the industry to simplify the pathway to transition for our customers, with partnerships across the supply chain to speed the development and commercialisation of more sustainable pMDIs.

Your most complete partner for pMDIs - from development to delivery

We’ll steer your pMDI from early development through to regulatory approval and commercial manufacturing, so you can get it into the hands of the patients who need it.

Our pMDI capabilities at a glance

  • Analytical & formulation development for solution and suspension pMDIs

  • pMDI product development - New Drug Applications (NDA), 505(b)(2) and generic pathways (ANDA)

  • Lab-scale filling with HFA-152a – ready now

  • Lab-scale filling with HF0-1234ze – ready now

  • Pilot-scale filling with HFA-152a – ready Q3 2024

  • Pilot-scale filling with HF0-1234ze – ready now

  • Commercial-scale filling with HFO-1234ze – ready now (process validation batches have been successfully manufactured)

  • Commercial-scale filling with HFA-152a – in progress, ready 2027

In 2023, we introduced Honeywell’s Solstice Air propellant at our Holmes Chapel, UK, manufacturing site to meet the needs of customers who want to replace the high global warming potential (GWP) propellants they are using today with a near-zero GWP alternative, without sacrificing patient performance

Chris Hirst , CEO

Interested in green propellants and sustainable pMDIs? Contact our experienced team to learn how we can work together.

Critical Components for pMDIs